This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Onconova (ONTX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on pipeline updates when Onconova (ONTX) reports Q2 results.
Teva (TEVA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Teva's (TEVA) second-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons Why Pacira (PCRX) Is a Great Growth Stock
by Zacks Equity Research
Pacira (PCRX) possesses solid growth attributes, which could help it handily outperform the market.
Zoetis (ZTS) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Ranked Momentum Stocks to Buy for July 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 21st
Vaxart (VXRT) Catches Eye: Stock Jumps 7.9%
by Zacks Equity Research
Vaxart (VXRT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Zacks.com featured highlights include: Nautilus, Ameresco, Canadian Solar, Emergent BioSolutions and Pacira BioSciences
by Zacks Equity Research
Zacks.com featured highlights include: Nautilus, Ameresco, Canadian Solar, Emergent BioSolutions and Pacira BioSciences
5 Stocks With Recent Price Strength Despite Market Volatility
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4%
by Zacks Equity Research
Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Otonomy (OTIC) Catches Eye: Stock Jumps 9.1%
by Zacks Equity Research
Otonomy (OTIC) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Verrica (VRCA) in Focus: Stock Moves 8.9% Higher
by Zacks Equity Research
Verrica (VRCA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for July 10th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 10th
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
Pacira (PCRX) Provides Preliminary Results for Second Quarter
by Zacks Equity Research
Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic. The stock fell in pre-market trading.
4 Small Drug Stocks Worth Betting on Amid Coronavirus Woes
by Zacks Equity Research
Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.
Will Pacira BioSciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Pacira BioSciences
Pacira (PCRX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Pacira (PCRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Is Pacira (PCRX) Up 14.6% Since Last Earnings Report?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PCRX vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PCRX vs. ZTS: Which Stock Is the Better Value Option?
Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.
Pacira (PCRX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 65.62% and 4.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PCRX or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PCRX vs. CTLT: Which Stock Is the Better Value Option?
Pacira (PCRX) Down 37.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.